## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no access to full manuscript, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors propose ChemGLaM, a chemical genomics language model integrating pre-trained chemical and protein language models via a cross-attention interaction block, claiming state-of-the-art performance in CPI prediction, enhanced virtual screening success via uncertainty estimation and attention visualization, and practical applicability demonstrated through a public database and ALS drug/target exploration
- **Visible evidence base** Abstract text only; no quantitative results, benchmark details, or methodological specifics provided
- **Missing materials affecting confidence** Full manuscript, all figures and tables, benchmark datasets, baseline comparisons, uncertainty estimation methodology, attention visualization examples, database implementation details, ALS case study results

## Reviewer
- **Overall assessment** The abstract presents a conceptually appealing integration of established techniques, namely cross-attention fusion of protein and chemical language models, with uncertainty estimation and explainability. However, the abstract lacks quantitative evidence, methodological novelty is unclear relative to existing CPI models, and the practical claims, particularly regarding ALS exploration, are unsubstantiated in the provided material. The work may be of interest to the computational drug discovery community, but the case is not established from the abstract alone.
- **Who would be interested in the results, and why** Computational biologists, medicinal chemists, and AI researchers focused on drug discovery would be interested. The combination of CPI prediction, uncertainty quantification, and explainability addresses practical needs in virtual screening and target identification, which are central to reducing attrition in early-stage drug development.
- **Major strengths** The abstract clearly identifies three practical requirements for CPI models, namely generalization, confidence quantification, and explainability, and proposes a unified framework addressing all three. The integration of pre-trained language models with cross-attention is a sensible architectural choice. The mention of a public database and ALS application suggests an effort toward translational impact.
- **Major Concerns**  
  - R1-M1  
  - R1-M2  
  - R1-M3  
  - R1-M4
- **Minor Comments**  
  - R1-m1  
  - R1-m2  
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3, R1-M4
- **Assessment against Nature-style criteria** Originality is moderate, as the architecture combines known components without clear conceptual innovation. Scientific importance is potentially high given the practical relevance, but the abstract does not demonstrate a significant advance over existing methods. Interdisciplinary readership is plausible, but the abstract lacks sufficient technical detail for specialists and sufficient context for nonspecialists. Technical soundness cannot be assessed without quantitative results. Readability for nonspecialists is adequate but would benefit from clearer articulation of the specific contributions.
- **Recommendation posture** Currently not established from the provided evidence. The abstract promises substantial results, but without data, benchmarks, or methodological detail, the claims cannot be evaluated. A revised submission with full evidence would be required for a supportive posture.

### Major Concerns

- **Concern ID** R1-M1  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence sufficiency  
- **Claim pointer** "achieving state-of-the-art performance in predicting novel CPIs"  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The abstract claims state-of-the-art performance but provides no quantitative metrics, benchmark datasets, or comparison baselines.  
- **Why it matters** Without specific performance numbers and comparative evaluation, the claim of state-of-the-art is unverifiable and could be misleading.  
- **Resolution test** Provide performance metrics, such as AUC, precision, recall, or F1, on standard CPI benchmarks, with explicit comparison to existing methods.

- **Concern ID** R1-M2  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Methodological clarity  
- **Claim pointer** "integrates independently pre-trained chemical and protein language models through an interaction block with a cross-attention mechanism"  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The abstract does not describe how the cross-attention mechanism operates, how the interaction block is designed, or how the pre-trained models are adapted.  
- **Why it matters** Reproducibility and assessment of technical novelty require a clear description of the model architecture and training procedure.  
- **Resolution test** Include a detailed architecture description, training details, and hyperparameters in the full manuscript.

- **Concern ID** R1-M3  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence sufficiency  
- **Claim pointer** "enhance the success rate of virtual screening and to provide molecular insights into CPIs"  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The abstract claims that uncertainty estimation and attention visualization improve virtual screening success and provide molecular insights, but no results are presented to support these claims.  
- **Why it matters** These are central practical benefits of the proposed method, and without evidence, the claims remain speculative.  
- **Resolution test** Provide case studies or quantitative evaluations showing improved screening hit rates and examples of attention-based insights validated experimentally or against known interactions.

- **Concern ID** R1-M4  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence sufficiency  
- **Claim pointer** "demonstrate its practical applicability by constructing a public database for large-scale CPI predictions and enabling drug/target exploration for candidate treatment of amyotrophic lateral sclerosis (ALS)"  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The abstract mentions a public database and ALS exploration but provides no details on database scale, accessibility, or the ALS findings.  
- **Why it matters** Practical applicability is a key selling point, and the lack of specifics prevents assessment of the translational value.  
- **Resolution test** Describe the database contents, access method, and present ALS-related predictions with any experimental validation or literature support.

### Minor Comments

- **Concern ID** R1-m1  
- **Severity** Minor  
- **Axis** Clarity  
- **Affected element** Terminology  
- **Evidence pointer** Abstract, location not provided  
- **Issue** The term "chemical genomics language model" is not defined or contextualized.  
- **Required correction** Define the term and explain how it relates to existing language model approaches in chemistry and biology.

- **Concern ID** R1-m2  
- **Severity** Minor  
- **Axis** Scope  
- **Affected element** Generalization claim  
- **Evidence pointer** Abstract, location not provided  
- **Issue** The claim of "high generalization performance" is vague and not tied to specific evaluation settings, such as cold-start or scaffold split scenarios.  
- **Required correction** Specify the evaluation protocols used to assess generalization.

- **Concern ID** R1-m3  
- **Severity** Minor  
- **Axis** Readability  
- **Affected element** Abstract structure  
- **Evidence pointer** Abstract, location not provided  
- **Issue** The abstract moves from technical claims to practical applications without a clear logical transition.  
- **Required correction** Reorganize the abstract to first state the problem, then the method, followed by key results, and finally the practical implications.

## Risk / unsupported claims
- State-of-the-art performance claim is unsupported without quantitative benchmarks.
- Enhanced virtual screening success rate is unsupported without experimental or simulation results.
- Molecular insights from attention visualization are unsupported without examples or validation.
- Practical applicability via public database and ALS exploration is unsupported without database details or ALS findings.
- Generalization performance claim is unverifiable without evaluation protocol specifics.